Bob Bradway, Amgen CEO (Scott Eisen/Bloomberg via Getty Images)
August 5, 2022 07:19 AM EDTUpdated 01:41 PM
Pharma
Marketing

Am­gen diss­es drug pric­ing bill, while amp­ing $4B rare drug com­pa­ny deal and up­com­ing Hu­mi­ra biosim launch

Beth Snyder Bulik

Senior Editor

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Supreme Court to keep mulling state PBM dis­pute as US urges jus­tices to de­cline case

Large phar­ma com­pa­nies spell out rea­sons why tar­iffs will harm US in­vest­ments 

Mer­ck, Dai­ichi Sankyo scrap FDA ap­pli­ca­tion for HER3 ADC af­ter sur­vival miss

DNA gi­ant Il­lu­mi­na spawned an ecosys­tem of com­peti­tors and cus­tomers

FDA re­jects Stealth's rare dis­ease drug, but of­fers po­ten­tial for ac­cel­er­at­ed ap­proval

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times